Mathers BM, et al.
Mortality among people who inject drugs: a systematic review and meta-analysis. Bulletin of the World Health Organization
2013; 91: 102–123.
Iversen J, et al.
Reduction in HCV incidence among injection drug users attending needle and syringe programs in Australia: a linkage study. American Journal of Public Health
2013; 103: 1436–1444.
Martin NK, et al.
Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. Hepatology
2013; 58: 1598–1609.
Wiessing L, et al.
Hepatitis C virus infection epidemiology among people who inject drugs in Europe: a systematic review of data for scaling up treatment and prevention. PLoS ONE
2014; 9: e103345.
De Vos AS, et al.
Decline in incidence of HIV and hepatitis C virus infection among injecting drug users in Amsterdam; evidence for harm reduction?
2013; 108: 1070–1081.
Craine N, et al.
Incidence of hepatitis C in drug injectors: the role of homelessness, opiate substitution treatment, equipment sharing, and community size. Epidemiology and Infection
2009; 137: 1255–1265.
Bravo MJ, et al.
HCV seroconversion among never-injecting heroin users at baseline: no predictors identified other than starting injection. International Journal of Drug Policy
2012; 23: 415–419.
Sun H-Y, et al.
Recent hepatitis C virus infections in HIV-infected patients in Taiwan: incidence and risk factors. Journal of Clinical Microbiology
2012; 50: 781–787.
Luciani F, et al.
A prospective study of hepatitis C incidence in Australian prisoners. Addiction
2014; 109: 1695–1706.
Balogun M, et al.
Prevalence and incidence of hepatitis C in injecting drug users attending genitourinary medicine clinics. Epidemiology and Infection
2009; 137: 980–987.
Page-Shafer K, et al.
Testing strategy to identify cases of acute hepatitis C virus (HCV) infection and to project HCV incidence rates. Journal of Clinical Microbiology
2008; 46: 499–506.
Hope V, et al.
Measuring the incidence, prevalence and genetic relatedness of hepatitis C infections among a community recruited sample of injecting drug users, using dried blood spots. Journal of Viral Hepatitis
2011; 18: 262–270.
Busch MP, Shafer KAP. Acute-phase hepatitis C virus infection: implications for research, diagnosis, and treatment. Clinical Infectious Diseases
2005; 40: 959–961.
Brant L, et al.
Diagnosis of acute hepatitis C virus infection and estimated incidence in low-and high-risk English populations. Journal of Viral Hepatitis
2008; 15: 871–877.
Cullen K, et al.
Factors associated with recently acquired hepatitis C virus infection in people who inject drugs in England, Wales and Northern Ireland: new findings from an unlinked anonymous monitoring survey. Epidemiology and Infection
2015; 143: 1398–1407.
Shepherd SJ, et al.
A hepatitis C avidity test for determining recent and past infections in both plasma and dried blood spots. Journal of Clinical Virology
2013; 57: 29–35.
Patel EU, et al.
Use of hepatitis C virus (HCV) immunoglobulin G antibody avidity as a biomarker to estimate the population-level incidence of HCV infection. Journal of Infectious Diseases
Gaudy-Graffin C, et al.
Use of an anti-hepatitis C virus (HCV) IgG avidity assay to identify recent HCV infection. Journal of Clinical Microbiology
2010; 48: 3281–3287.
Jauffret-Roustide M, et al.
A national cross-sectional study among drug-users in France: epidemiology of HCV and highlight on practical and statistical aspects of the design. BMC Infectious Diseases
2009; 9: 1.
Weill-Barillet L, et al.
Hepatitis C virus and HIV seroprevalences, sociodemographic characteristics, behaviors and access to syringes among drug users, a comparison of geographical areas in France, ANRS-Coquelicot 2011 survey. Revue d'Épidémiologie et de Santé Publique
Leon L, Jauffret-Roustide M, Le Strat Y. Design-based inference in time-location sampling. Biostatistics
2015; 16: 565–579.
Semaille C, et al.
Monitoring the dynamics of the HIV epidemic using assays for recent infection and serotyping among new HIV diagnoses: experience after 2 years in France. Journal of Infectious Diseases
2007; 196: 377–383.
Bollaerts K, et al.
Estimating the population prevalence and force of infection directly from antibody titres. Statistical Modelling
2012; 12: 441–462.
Korn EL, Graubard BI. Analysis of Health Surveys: John Wiley & Sons, 2011.
Binder H, Sauerbrei W, Royston P. Comparison between splines and fractional polynomials for multivariable model building with continuous covariates: a simulation study with continuous response. Statistics in Medicine
2013; 32: 2262–2277.
Royston P, Ambler G, Sauerbrei W. The use of fractional polynomials to model continuous risk variables in epidemiology. International Journal of Epidemiology
1999; 28: 964–974.
Shkedy Z, et al.
Modelling age-dependent force of infection from prevalence data using fractional polynomials. Statistics in Medicine
2006; 25: 1577–1591.
Cousien A, et al.
Dynamic modelling of hepatitis C virus transmission among people who inject drugs: a methodological review. Journal of Viral Hepatitis
2015; 22: 213–229.
Le Page A, Robertson P, Rawlinson W. Discordant hepatitis C serological testing in Australia and the implications for organ transplant programs. Journal of Clinical Virology
2013; 57: 19–23.
Smit C, et al.
Risk of hepatitis-related mortality increased among hepatitis C virus/HIV-coinfected drug users compared with drug users infected only with hepatitis C virus: a 20-year prospective study. JAIDS Journal of Acquired Immune Deficiency Syndromes
2008; 47: 221–225.
Horvitz DG, Thompson DJ. A generalization of sampling without replacement from a finite universe. Journal of the American statistical Association
1952; 47: 663–685.
Lucidarme D, et al.
Incidence and risk factors of HCV and HIV infections in a cohort of intravenous drug users in the North and East of France. Epidemiology and Infection
2004; 132: 699–708.
Anon. Hepatitis C in the UK. Public Health England, 2014.
Wandeler G, et al.
Hepatitis C virus infections in the Swiss HIV Cohort Study: a rapidly evolving epidemic. Clinical Infectious Diseases
Jauffret-Roustide M, et al. High biological-based HCV incidence and increasing frequency of high-risk practices among IDUs in Paris: What are the implications for harm reduction models? First European Conference on Addictive Behaviours and Dependencies, 2015.
Martin NK, et al.
Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations. Hepatology
2012; 55: 49–57.
Jauffret-Roustide M, Pedrono G, Beltzer N. Supervised consumption rooms: the French Paradox. International Journal of Drug Policy
2013; 24: 628–630.
Castro Sanchez AY, et al.
A mathematical model for HIV and hepatitis C co-infection and its assessment from a statistical perspective. Epidemics
2013; 5: 56–66.
Hagan H, et al.
Hepatitis C virus infection among HIV-positive men who have sex with men: protocol for a systematic review and meta-analysis. Systematic reviews
2014; 3: 1.
Cousien A, et al.
Hepatitis C treatment as prevention of viral transmission and liver-related morbidity in persons who inject drugs. Hepatology